Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure

AIMS: In this prospective, placebo‐controlled, double‐blind, exploratory study, we examined early and more delayed effects of empagliflozin treatment on haemodynamic parameters (primary endpoint: cardiac output) and kidney function including parameters of acute kidney injury (AKI) in patients with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Thiele, Kirsten, Rau, Matthias, Hartmann, Niels‐Ulrik Korbinian, Möller, Marcus, Möllmann, Julia, Jankowski, Joachim, Keszei, András P., Böhm, Michael, Floege, Jürgen, Marx, Nikolaus, Lehrke, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288802/
https://www.ncbi.nlm.nih.gov/pubmed/35611683
http://dx.doi.org/10.1002/ehf2.13955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288802/
https://www.ncbi.nlm.nih.gov/pubmed/35611683
http://dx.doi.org/10.1002/ehf2.13955

Ejemplares similares